Theravance Biopharma
TBPH
123 hedge funds and large institutions have $648M invested in Theravance Biopharma in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 27 reducing their positions, and 13 closing their positions.
126% more call options, than puts
Call options by funds: $9.48M | Put options by funds: $4.19M
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
70% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 27
14% more capital invested
Capital invested by funds: $568M → $648M (+$80.2M)
9% more funds holding
Funds holding: 113 → 123 (+10)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.54% less ownership
Funds ownership: 84.39% → 83.85% (-0.54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$11.4M |
| 2 |
Two Sigma Advisers
New York
|
+$6.53M |
| 3 |
Two Sigma Investments
New York
|
+$6.12M |
| 4 |
Millennium Management
New York
|
+$6.1M |
| 5 |
NM
Newtyn Management
New York
|
+$4.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$19.9M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$11.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.05M |
| 4 |
MAP
Madison Avenue Partners
New York
|
-$2.41M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$2.29M |
TBPH Hedge Fund Activity: Q3 2022 in Review
123 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2022, worth a combined $648M — up 14% from $568M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new TBPH positions and 13 closed out — a net gain of 10 holders — while 46 added to existing stakes and 27 trimmed.
The largest buyer was Weiss Asset Management, adding an estimated $11.4M. The largest seller was Woodline Partners, cutting an estimated $19.9M.
- 123 institutional investors held Theravance Biopharma (TBPH) as of Q3 2022, up from 113 in Q2 2022.
- Funds reported $648M of Theravance Biopharma stock for Q3 2022, up 14% quarter-over-quarter.
- 23 funds opened new Theravance Biopharma positions in Q3 2022 and 13 closed out, a net change of +10 holders.
- The largest Theravance Biopharma buyer in Q3 2022 was Weiss Asset Management, an estimated $11.4M added.
- The largest Theravance Biopharma seller in Q3 2022 was Woodline Partners, an estimated $19.9M sold.
Based on aggregated 13F filings for Q3 2022.